Allergy Immunotherapy

Continuing Education Activity

Allergy desensitization, also termed allergen immunotherapy (AIT) or hyposensitization, was first introduced by Leonard Noon in 1911, who proposed that people with hay fever were sensitive to grass pollen toxins. Desensitization is "a method to develop a temporary state of tolerance to an agent responsible for an allergic or hypersensitivity reaction." This activity reviews the indications, contraindications, and techniques for allergy desensitization and highlights the interprofessional team's role in the management of patients with allergies.


  • Explain how allergy desensitization is done.
  • Describe the indications for allergy desensitization.
  • Review the clinical relevance of allergy desensitization.
  • Outline the importance of collaboration and coordination amongst the interprofessional team in optimizing the care of patients requiring allergy desensitization.


Allergy desensitization, allergen immunotherapy (AIT), or hypo-sensitization, was first introduced by Leonard Noon in 1911, who proposed that people with hay fever were sensitive to grass pollen toxins.[1] Desensitization is "a method to develop a temporary state of tolerance to an agent responsible for an allergic or hypersensitivity reaction."[2] It is a disease-modifying treatment and lasts longer even after stopping the treatment, providing prophylactic effects.[3][4][5][6][7][8]

Immunotherapy is the treatment of allergic disease by promoting or suppressing immunity. Allergen immunotherapy is a group of therapies that seek to promote immune tolerance to allergens.[2] Hyposensitization is a term formerly used as synonymous with allergen immunotherapy because complete desensitization is rare with immunotherapy.

Types of Allergic or Hypersensitivity Disorders

Respiratory tract disorders include allergic rhinitis, allergic aspergillus rhinosinusitis, allergic bronchopulmonary aspergillosis (ABPA), or allergic asthma.[2] Ocular disorders include allergic conjunctivitis, vernal keratoconjunctivitis, and atopic keratoconjunctivitis. [2] Skin and mucous membranes disorders include allergic contact urticaria, oral allergy syndrome, acute urticaria due to IgE-mediated allergy, and atopic eczema.[2] Drug hypersensitivity includes exanthematous drug eruption, drug-induced urticaria, angioedema and anaphylaxis, and Samter syndrome.[2] Food hypersensitivity includes food-induced urticaria, angioedema anaphylaxis, IgE-mediated food-induced gastrointestinal hypersensitivity, and oral allergy syndrome.[2] Insect hypersensitivity or allergies include anaphylaxis, cutaneous reactions or local reaction to Hymenoptera venom.

Anatomy and Physiology

Several cellular and molecular mechanisms explain the beneficial effects of immunotherapy, including allergic specific suppression of inducible CD4(+), CD 25+, forkhead box p3+ T-regulatory cells, and IL-10 secreting T-regulatory cells; preventing their increase in peripheral blood. Other mechanisms include suppressing eosinophils, mast cells, basophils, and antibody switch from IgE to IgG4.[9]


 Indications for Desensitization[1][2]

  • Moderate-to-severe symptoms of allergic rhinitis
  • Allergic asthma
  • Allergic conjunctivitis
  • Allergic rhino-conjunctivitis
  • Atopic dermatitis
  • Immune-mediated and IgE-mediated food allergy
  • Insect allergy that causes significant local reaction and anaphylaxis

Other Immunotherapies[2]

  • Vaccination and biological agents in infectious disease and primary immunodeficiencies.
  • Immunosuppressive agents in autoimmune disease and organ transplant
  • Biological and monoclonal agents
  • Food hypersensitivity


  • No evidence of the effectiveness of immunotherapy if specific IgE antibodies test results are negative[2]
  • When suspected clinical symptoms and exposure do not correlate with positive IgE test results[2]


Required Equipment and Procedures[3]

  • All extracts require storage in a refrigerator at 4 degrees C
  • Administration is via subcutaneous injection
  • Seventy percent isopropanol for sanitization
  • Sterile syringes and vials
  • Mixing log
  • Policy and procedure manual


Because the allergy desensitization process can cause severe reactions, including anaphylaxis, a physician should supervise trained personnel.[3] The required training is:

  • Preparation of allergenic products
  • Successful completion of a written test on aseptic technique and extract preparation and media-fill testing
  • Knowledge of antiseptic hand cleaning and disinfection of mixing surfaces
  • Ability to identify, measure, and mix ingredients


The prescribing physician should select allergen extracts. The physician should consider several important factors, including the quality of allergen extracts, cross-reactivity, and degradation of allergens and immunotherapy doses; for example, the starting dose will be lower than the maintenance dose.[3]


Allergenic proteins from pollen, dander, dust mites, insects, mold, among others, are the main ingredient of allergen extract. However, the final product is a mixture of diluents or solvents and preservatives. Different extracts, including aqueous, glycerinated, lyophilized, acetone precipitated, alum-precipitated are available. Diluents will keep the allergen in liquid form; commonly used agents are glycerin, phenol saline, and HSA. The staff should use measures that include good personal hygiene, hand washing, and antiseptics to clean working areas. These include a water-based disinfectant followed by the application of alcohol on working surfaces for preparing allergen extracts. Alcohol kills organisms by dehydration. Sanitization will prevent bacterial contamination.[3]


Complications include systemic reactions like anaphylaxis and a local reaction at the injection site.[3]

Management of Complications[3]

  • Topical corticosteroids, antihistamines, or cool compresses for local reaction
  • Epinephrine is the mainstay treatment for anaphylaxis.

The physician should re-visit the benefit versus risk of continuing immunotherapy after systemic reactions.[3]

Clinical Significance


Allergen immunotherapy can reduce short-term symptoms in allergic asthma; however, there is a moderate increase in the risk of systemic and local reactions based on a meta-analysis.[6] A 3-year course of either sublingual or subcutaneous immunotherapy prevents asthma for up to 2 years in children and adolescents with grass/birch pollen that triggers moderate to severe allergic rhinitis; however, this still requires further research.[4]

Allergic Rhinitis

  • Allergen immunotherapy is clinically effective, cost-effective, and disease-modifying in allergic rhinitis compared to standard drugs.[10][11]
  • Sublingual immunotherapy for pediatric allergic rhinitis has shown improvement in symptomatic management and a decreased medication need based on a meta-analysis of the randomized controlled trials. More trials with a larger sample size are underway to assess safety in the pediatric population.[12]

Allergic Rhino-Conjunctivitis

Allergen immunotherapy has shown benefit in improving rhino-conjunctivitis symptoms[13]. Some evidence suggests that there is a maintenance effect on reducing symptoms after discontinuation of immunotherapy.[14]

Enhancing Healthcare Team Outcomes

Current and Future Trends in Allergen Immunotherapy

There are different approaches to providing safety and overcoming the risk of severe adverse allergic reactions during immunotherapy. The data from the meta-analysis suggest new allergen preparations available are allergoids, recombinant allergens (recA), and modified-recombinant allergens (recA). Studies on virus-like-particles and CpG-motifs, adjuvants like MPL, and aluminum hydroxide have been shown to increase immunological response and improve safety and efficacy.[8] The latest approaches to allergen immunotherapy include the application of extract patches on the skin and/or inguinal lymph node injection. Recombinant technology or chemicals may alter allergen molecules that make them less reactive; this may be due to suppressing Th2 responses or stimulation of toll-like receptors (approval is pending).[15] The new advances in allergy immunotherapy provide disease-modifying treatments and are also cost-effective and improve the quality of life.[16] The major allergen Bet v 1 involved in birch pollen allergy may be the future of allergen immunotherapy for rhinoconjunctivitis.[17]

Doses, Delivery, and Application of Immunotherapy 

  • Comparing pediatric and adult systemic reactions to subcutaneous immunotherapy shows significant grade 1 and Grade 2 systemic reactions that are higher in a pediatric population than adults. However, further studies are needed to evaluate the dosing strategy in children.[18]
  • Subcutaneous allergen immunotherapy has shown that SCIT rarely causes any major clinical problems; there is a risk of less than 1.5% in patients who are HIV positive without AIDS, cancer (in remission), severe asthma, transplantation,  and during pregnancy, based on web-based survey.[19]
  • Subcutaneous immunotherapy has the lowest risk of an allergic reaction ranking compared with 3 different methods of delivering immunotherapy; sublingual liquid (SLIT), sublingual tablets (AIT), and oral mucosal therapy (OMIT) using toothpaste. However, there are no significant differences between any of these delivery options. The most convenient factor for most patients is home immunotherapy administration.[20]

When using allergy desensitization, an interprofessional team including clinicians, mid-level practitioners nursing staff, and pharmacists is the best approach to achieving improved patient outcomes.

Article Details

Article Author

Yudy Persaud

Article Author

Ruba Memon

Article Editor:

Mohammedi Savliwala


4/17/2021 11:03:00 PM

PubMed Link:

Allergy Immunotherapy



Smith CS, Allergen immunotherapy practice parameter update. The Journal of the Kentucky Medical Association. 2004 Feb     [PubMed PMID: 15004935]


Tanno LK,Calderon MA,Papadopoulos NG,Sanchez-Borges M,Rosenwasser LJ,Bousquet J,Pawankar R,Sisul JC,Cepeda AM,Li J,Muraro A,Fineman S,Sublett JL,Katelaris CH,Chang YS,Moon HB,Casale T,Demoly P, Revisiting Desensitization and Allergen Immunotherapy Concepts for the International Classification of Diseases (ICD)-11. The journal of allergy and clinical immunology. In practice. 2016 Jul-Aug     [PubMed PMID: 26969269]


Cox L,Nelson H,Lockey R,Calabria C,Chacko T,Finegold I,Nelson M,Weber R,Bernstein DI,Blessing-Moore J,Khan DA,Lang DM,Nicklas RA,Oppenheimer J,Portnoy JM,Randolph C,Schuller DE,Spector SL,Tilles S,Wallace D, Allergen immunotherapy: a practice parameter third update. The Journal of allergy and clinical immunology. 2011 Jan     [PubMed PMID: 21122901]


Halken S,Larenas-Linnemann D,Roberts G,Calderón MA,Angier E,Pfaar O,Ryan D,Agache I,Ansotegui IJ,Arasi S,Du Toit G,Fernandez-Rivas M,Geerth van Wijk R,Jutel M,Kleine-Tebbe J,Lau S,Matricardi PM,Pajno GB,Papadopoulos NG,Penagos M,Santos AF,Sturm GJ,Timmermans F,van Ree R,Varga EM,Wahn U,Kristiansen M,Dhami S,Sheikh A,Muraro A, EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2017 Dec     [PubMed PMID: 28902467]


Di Lorenzo G,Leto-Barone MS,La Piana S,Plaia A,Di Bona D, The effect of allergen immunotherapy in the onset of new sensitizations: a meta-analysis. International forum of allergy     [PubMed PMID: 28544523]


Dhami S,Kakourou A,Asamoah F,Agache I,Lau S,Jutel M,Muraro A,Roberts G,Akdis CA,Bonini M,Cavkaytar O,Flood B,Gajdanowicz P,Izuhara K,Kalayci Ö,Mosges R,Palomares O,Pfaar O,Smolinska S,Sokolowska M,Asaria M,Netuveli G,Zaman H,Akhlaq A,Sheikh A, Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy. 2017 Dec     [PubMed PMID: 28543086]


Kristiansen M,Dhami S,Netuveli G,Halken S,Muraro A,Roberts G,Larenas-Linnemann D,Calderón MA,Penagos M,Du Toit G,Ansotegui IJ,Kleine-Tebbe J,Lau S,Matricardi PM,Pajno G,Papadopoulos NG,Pfaar O,Ryan D,Santos AF,Timmermanns F,Wahn U,Sheikh A, Allergen immunotherapy for the prevention of allergy: A systematic review and meta-analysis. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2017 Feb     [PubMed PMID: 27653623]


Klimek L,Pfaar O,Bousquet J,Senti G,Kündig T, Allergen immunotherapy in allergic rhinitis: current use and future trends. Expert review of clinical immunology. 2017 Sep     [PubMed PMID: 28532268]


Jutel M,Akdis CA, Immunological mechanisms of allergen-specific immunotherapy. Allergy. 2011 Jun     [PubMed PMID: 21466562]


Cox L, The role of allergen immunotherapy in the management of allergic rhinitis. American journal of rhinology     [PubMed PMID: 26867530]


Nelson HS,Makatsori M,Calderon MA, Subcutaneous Immunotherapy and Sublingual Immunotherapy: Comparative Efficacy, Current and Potential Indications, and Warnings--United States Versus Europe. Immunology and allergy clinics of North America. 2016 Feb     [PubMed PMID: 26617224]


Feng B,Wu J,Chen B,Xiang H,Chen R,Li B,Chen S, Efficacy and safety of sublingual immunotherapy for allergic rhinitis in pediatric patients: A meta-analysis of randomized controlled trials. American journal of rhinology     [PubMed PMID: 28234149]


Pfaar O,Demoly P,Gerth van Wijk R,Bonini S,Bousquet J,Canonica GW,Durham SR,Jacobsen L,Malling HJ,Mösges R,Papadopoulos NG,Rak S,Rodriguez del Rio P,Valovirta E,Wahn U,Calderon MA, Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014 Jul     [PubMed PMID: 24761804]


Dhami S,Nurmatov U,Arasi S,Khan T,Asaria M,Zaman H,Agarwal A,Netuveli G,Roberts G,Pfaar O,Muraro A,Ansotegui IJ,Calderon M,Cingi C,Durham S,van Wijk RG,Halken S,Hamelmann E,Hellings P,Jacobsen L,Knol E,Larenas-Linnemann D,Lin S,Maggina P,Mösges R,Oude Elberink H,Pajno G,Panwankar R,Pastorello E,Penagos M,Pitsios C,Rotiroti G,Timmermans F,Tsilochristou O,Varga EM,Schmidt-Weber C,Wilkinson J,Williams A,Worm M,Zhang L,Sheikh A, Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy. 2017 Nov     [PubMed PMID: 28493631]


Nelson HS, Allergen immunotherapy now and in the future. Allergy and asthma proceedings. 2016 Jul     [PubMed PMID: 27401313]


Reisacher WR,Schwanke T, New advances in allergy immunotherapy. Current opinion in otolaryngology     [PubMed PMID: 26926847]


Moingeon P,Floch VB,Airouche S,Baron-Bodo V,Nony E,Mascarell L, Allergen immunotherapy for birch pollen-allergic patients: recent advances. Immunotherapy. 2016 May     [PubMed PMID: 27140409]


Lim CE,Sison CP,Ponda P, Comparison of Pediatric and Adult Systemic Reactions to Subcutaneous Immunotherapy. The journal of allergy and clinical immunology. In practice. 2017 Sep - Oct     [PubMed PMID: 28341172]


Larenas-Linnemann DE,Hauswirth DW,Calabria CW,Sher LD,Rank MA, American Academy of Allergy, Asthma & Immunology membership experience with allergen immunotherapy safety in patients with specific medical conditions. Allergy and asthma proceedings. 2016 Sep     [PubMed PMID: 27657518]


Chester JG,Bremberg MG,Reisacher WR, Patient preferences for route of allergy immunotherapy: a comparison of four delivery methods. International forum of allergy     [PubMed PMID: 26833457]